Valeant Pharmaceuticals Trading Higher Pre-Market (VRX)

by BenzingaStaffJ, Benzinga Staff Writer
March 30, 2011 8:36 AM | 12 seconds read |
Valeant Pharmaceuticals VRX is trading higher pre-market. At the time of posting, shares of VRX were at $51.50, up 16.02% from Tuesday's close. Valeant has proposed to acquire Cephalon for $73/sh according to Cephalon.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Pre-Market OutlookHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!